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COMMENTARY

Clinical Data: Sources and Types, Regulatory Constraints,
Applications
Stanley C. Ahalt1,†, Christopher G. Chute2, Karamarie Fecho1,*, Gustavo Glusman3, Jennifer Hadlock3, Casey Overby Taylor2,
Emily R. Pfaff4, Peter N. Robinson5, Harold Solbrig2, Casey Ta6, Nicholas Tatonetti6 and Chunhua Weng6 The Biomedical Data
Translator Consortium

Access to clinical data is critical for the advancement of translational research. However, the numerous regulations and policies that surround
the use of clinical data, although critical to ensure
patient privacy and protect against misuse, often
present challenges to data access and sharing. In
this article, we provide an overview of clinical
data types and associated regulatory constraints
and inferential limitations. We highlight several
novel approaches that our team has developed
for openly exposing clinical data.
BACKGROUND
Recognizing the need to respect and protect patient privacy, numerous regulations have been established to govern the use of clinical data by researchers, including the
federal Health Insurance Portability and Accountability
Act of 1996 (HIPAA) and the European Union General Data
Protection Regulation. Institution-
specific guidelines and
governing bodies such as institutional review boards (IRBs)
also address research involving patient data and other sensitive data available in electronic medical records (e.g., administrative data), in part as a result of concerns regarding
the liability of healthcare providers and institutions.1,2
The Biomedical Data Translator (Translator) program,
funded by the National Center for Advancing Translational
Sciences, aims to facilitate the transformation of basic science discoveries into clinically actionable knowledge and
leverage clinical expertise to drive research innovations.3,4
Access to clinical data is central to the vision of the program.
Yet, the program’s dedication to open science adds complexity to the regulatory, technical, and cultural challenges
that already surround access to clinical data.
We review here the types of clinical data sets that can
be derived from paper or electronic medical records, their
applications and limitations, and their associated regulatory
constraints, focusing primarily on compliance requirements
†
1

mandated in the United States under HIPAA (Table 1). We
briefly describe several clinical data types that are commonly employed in clinical and translational research, including fully identified clinical data, HIPAA-limited clinical
data, deidentified clinical data, and synthetic data. We highlight several novel approaches for openly exposing clinical data that we have developed as part of the Translator
program, namely, HIPAA Safe Harbor Plus (HuSH+) clinical
data, clinical profiles, Columbia Open Health Data (COHD),
and the Integrated Clinical and Environmental Exposures
Service (ICEES).
TYPES OF CLINICAL DATA SETS
Fully identified clinical data sets
Fully identified clinical data sets comprise observational
patient data, including direct patient identifiers (i.e., protected health information (PHI)), as defined in the privacy
rule issued under HIPAA. Access requires a specific research hypothesis, study approval by an IRB, a full or partial
waiver of HIPAA-informed consent, and typically a secure
workspace. For investigators not affiliated with a specific
institution, additional regulations and approvals may apply,
including a data use agreement (DUA) with the provider institution. Fully identified clinical data sets may be used for
clinical interpretation and scientific inference and discovery.
However, as with all data sets but especially observational
administrative data sets, issues of data quality and integrity
must be taken into account when drawing conclusions.1
HIPAA-limited clinical data sets
HIPAA-limited clinical data sets comprise observational patient data with limited PHI: dates such as admission, discharge, service, and dates of birth and death; city, state, and
five digits or more zip codes; and ages in years, months,
days, or hours. HIPAA-
limited clinical data sets may be
used or disclosed for purposes of research, public health,
or healthcare operations without obtaining patient authorization or a waiver of HIPAA-informed consent but with IRB
approval and (in some cases) a fully executed DUA. HIPAA-
limited clinical data sets may be used for clinical interpretation and scientific inference and discovery but with the
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understanding that certain data elements have been removed from the data and/or transformed (e.g., age vs. birth
date).
Deidentified clinical data sets
Deidentified clinical data sets comprise observational
patient data from which all PHI elements have been removed. Access to deidentified clinical data sets does
not require IRB approval, although an IRB Request for

Determination of Human Subjects Research is advised.
In addition, a fully executed DUA is sometimes required.
Deidentified clinical data sets may be used for clinical
interpretation and scientific inference and discovery
but to a lesser extent than HIPAA-limited clinical data
sets because of the fact that key variables or covariates
may have been removed from the data. For instance,
dates are 
required to make inferences regarding seasonal patterns in clinical outcomes and correlations with

Table 1 Clinical data types, regulatory access restrictions, and applications
Brief description

Clinical data type

Regulatory access restrictions

Applications
Clinical interpretation and
scientific inference and
discovery

Fully identified
clinical data sets

Observational patient data derived from
paper-based or electronic medical records

IRB approval is required; an executed
data use agreement is possibly
requireda

HIPAA-limited
clinical data sets

Observational patient data containing only a
limited set of HIPAA-defined PHI

IRB approval is required; an executed
data use agreement is possibly
requireda

Clinical interpretation and
scientific inference and
discovery, but with the
understanding that certain
data elements have been
removed from the data and/or
transformed

Deidentified clinical
data sets

Observational patient data, but with all HIPAA-
defined PHI elements removed

IRB approval is not requiredb; IRB
“Request for Determination of
Human Subjects Research” is
typically recommended; an executed
data use agreement is possibly
required

Clinical interpretation and
scientific inference and
discovery, but with the
understanding that inferences
regarding time and potentially
other factors cannot be made

HuSH+ clinical data
sets

Observational patient data, fully compliant with
HIPAA Safe Harbor, but unlike deidentified
clinical data sets, HuSH+ clinical data sets have
been altered such that (i) real patient identifiers
(including geocodes) have been replaced with
random patient identifiers and (ii) dates
(including birth dates) have been shifted by a
random number of days (maximum of
± 50 days), with all dates for a given patient
shifted by the same number of days
Data are derived from UNC Health Care System

An executed data use agreement is
requiredc

Clinical interpretation and
scientific inference and
discovery, but with the
understanding that any
inferences based on date/
time and location (geocode)
cannot be made with
precision, and all other
inferences must consider
date/time and location as
potentially hidden covariates

Statistical profiles of disease and associated
phenotypic presentation derived from
observational patient data
Data are derived from Johns Hopkins Medicine

IRB approval is required to generate
clinical profiles; no other restrictions
apply

Clinical interpretation and
scientific inference, but with
the understanding that the
data represent statistical
profiles

Clinical profiles

Synthetic clinical
data sets

Realistic, but not real, observational patient data
generated statistically using population
distributions of observational patient data

None

Feasibility assessments and
algorithm validation;
generation of clinical profiles

COHD

Counts of observational clinical co-occurrences
(e.g., co-occurrences of specific diagnoses and
prescribed medications), as well as their
relative frequency and observed–expected
frequency ratio
Data are derived from Columbia University
Irving Medical Center

None

Clinical interpretation and
scientific inference, but with
the understanding that the
data are restricted to
co-occurrences

ICEES

Patient-level or visit-level counts of observational
patient data integrated at the patient and visit
level with a variety of environmental exposures
derived from multiple public data sources
Data are derived from UNC Health Care System
and a variety of public data sources on
environmental exposures

IRB approval is required to generate
ICEES integrated feature tables; no
other restrictions apply

Clinical interpretation and
scientific inference, but with
the understanding that the
raw data have been
transformed (e.g., binned or
categorized)

COHD, Columbia Open Health Data; HIPAA, Health Insurance Portability and Accountability Act; HuSH+, HIPAA Safe Harbor Plus; ICEES, Integrated Clinical
and Environmental Exposures Service; IRB, institutional review board; PHI, protected health information; UNC, University of North Carolina.
a
Individual institutions may require a secure workspace for data access and use. bWhile HIPAA and IRB regulations do not apply, institutional approvals may
be required. cHuSH+ clinical data sets were conceptualized and created by UNC as part of the National Center for Advancing Translational Sciences–funded
Biomedical Data Translator program. The institution requires a fully executed data use agreement for access to the data.
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natural disasters, system-related issues such as protocol
changes, and regulatory issues such as new black-b ox
warnings.
HuSH+ clinical data sets
HuSH+ clinical data sets were created by Translator team
members as a hybrid deidentification approach that is completely compliant with HIPAA and provides restricted access
to observational patient data from the UNC Health Care
System. HuSH+ clinical data sets differ from deidentified clinical data sets in that (i) real patient identifiers (including geocodes) have been replaced with random patient identifiers and
(ii) dates (including birth dates) have been shifted by a random
number of days (maximum of ± 50 days), with all dates for a
given patient shifted by the same number of days. Access to
HuSH+ clinical data does not require IRB approval but does
require a fully executed DUA per institutional mandate. HuSH+
clinical data sets may be used in a limited fashion for clinical interpretation and scientific inference and discovery. The
main considerations are that any inferences based on date/
time and location (geocode) cannot be made with precise accuracy or correlated with seasonal trends or specific events,
and all other inferences must consider date/time and location
as potentially hidden covariates.
Clinical profiles
Clinical profiles have been developed as part of the Translator
program and represent statistical profiles of disease and associated phenotypic presentations derived from observational
patient data from Johns Hopkins Medicine using the Health
Level Seven International Fast Healthcare Interoperability
Resources common data model. At present, clinical profiles
include data on demographics, diagnoses, disease comorbidities, symptoms, medications, procedures, and laboratory measures. IRB approval is required to generate clinical
profiles but once generated, clinical profiles can be openly
shared. Institutional restrictions may apply, however. Clinical
profiles can be used for clinical interpretation and scientific
inference and discovery but with the understanding that they
represent statistical summaries of patient populations and
only indirectly represent patient-level observations. Multiple
computational tools and example output files are openly available for creating and using clinical profiles (see Supplemental
Information on Clinical Profiles in Further Reading).
Synthetic clinical data sets
Synthetic clinical data sets comprise realistic (but not real)
data generated statistically by applying simulation techniques
to population distributions of observational patient data.
Synthetic clinical data sets can be openly shared. A publicly
available example, the Synthetic Mass data set, was generated using the Synthea method5 to simulate patient-level and
population-level data on patients who reside in the state of
Massachusetts. A similar open effort is Simulacrum, which
is based on observational patient data held by Public Health
England’s National Cancer Registration and Analysis Service.
The data include realistic patient histories with clinically relevant patient encounters; as such, the data can be used for
feasibility assessments and algorithm validation but not for
clinical interpretation or scientific inference and discovery.

COHD
Translator team members have pioneered the use of clinical co-occurrence tables as part of the COHD initiative.6
COHD provides open access to observational patient data
from Columbia University Irving Medical Center in the form
of co-occurrence counts of pairs of concepts or clinical
feature variables (e.g., medications and diagnoses), as well
as their relative frequency and observed–expected frequency ratio. The data are publicly accessible via an open
web interface or Application Programming Interface. Risks
to patient privacy are mitigated by excluding rare features
(counts ≤ 10) and perturbing the counts according to the
Poisson distribution. The data can be used to derive insights into questions of clinical relevance and importance
for translational research. For instance, an individual user
may wish to know the frequency of asthma among African
American patients (Figure 1a). A search of the COHD service reveals that there are 11,716 African American patients with a diagnosis of asthma among 208,438 African
American patients (5.62%). For comparison, a second
search reveals that there are 29,913 white patients with a
diagnosis of asthma among 601,167 white patients (4.98%).
ICEES
ICEES was designed by Translator team members as a
novel extension of COHD.7 Specifically, ICEES permits
open access to observational patient data from the UNC
Health Care System that have been integrated at the patient and visit level with environmental exposures data (e.g.,
airborne and roadway pollutants, socioeconomic factors)
derived from multiple public sources. A complex data extraction and integration software pipeline has been developed to create ICEES integrated feature tables.8 The tables
are generated using PHI (geocodes and dates), but the data
are then binned or recoded and stripped of PHI. Thus, the
ICEES pipeline must be executed under an approved IRB
protocol, but subsequent steps are not subject to IRB regulation, and ICEES is publicly accessible via an Application
Programming Interface. ICEES provides a number of functionalities for clinical interpretation and scientific inference
and discovery. For example, Figure 1b demonstrates that
for COHORT:60 (African Americans with asthma-like conditions in calendar year 2010), the percentage of patients with
two or more annual emergency department or inpatient visits for respiratory issues is higher among patients with high
average daily exposure to particulate matter ≤ 2.5 μm in
diameter than among patients with low average daily exposure to particulate matter ≤ 2.5 μm in diameter (21.10% vs.
8.90%, P < 0.0001, N = 6,379), thus replicating published
literature on the association between airborne pollutant exposures and asthma exacerbations.9 The data additionally
suggest that African Americans with asthma-like conditions
have relatively high exposure to particulate matter, with
~ 95% of the cohort exposed to ≥ 9.63 μg/m3 average daily
particulate matter ≤ 2.5 μm in diameter.
Clinical fingerprints
Although not a new clinical data type per se, Translator
teams have been working to develop privacy-preserving
analytic approaches to visualize and compare patient data,
www.cts-journal.com
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(a) COHD example queries

Input: Asthma

(ID #317009) and Black or African American (ID #8516)

Output:

Input: Asthma

(ID #317009) and White (ID #8527)

Output:

(b) ICEES example query

Input:
Feature variables: AvgDailyPM2.5Exposures < 3, TotalEDInpatientVisits < 2
Version of data: 1.0.0
Table: patient
Year: 2010
Cohort ID: COHORT:60

Output:*
+----------------------------+------------------------------+-------------------------------+---------+
| feature
| TotalEDInpatientVisits < 2
| TotalEDInpatientVisits >= 2
|
|
+============================+==============================+===============================+=========+
| AvgDailyPM2.5Exposure < 3 | 297
91.10%
| 29
8.90%
| 326
|
|
| 5.85% 4.66%
| 2.22% 0.45%
| 5.11%
|
+----------------------------+------------------------------+-------------------------------+---------+
| AvgDailyPM2.5Exposure >= 3 | 4776
78.90%
| 1277
21.10%
| 6053
|
|
| 94.15% 74.87%
| 97.78% 20.02%
| 94.89% |
+----------------------------+------------------------------+-------------------------------+---------+
|
| 5073
| 1306
| 6379
|
|
| 79.53%
| 20.47%
| 100.00% |
+----------------------------+------------------------------+-------------------------------+---------+
+-------------+---------------+
|
p_value |
chi_squared |
+=============+===============+
| 3.16593e-06 |
28.2841 |
+-------------+---------------+

Figure 1 Example queries, including input parameters and output, for Columbia Open Health Data (COHD) (a) and the Integrated
Clinical and Environmental Exposures Service (ICEES) (b). AvgDailyPM2.5Exposure = average daily patient exposure to PM2.5 (μg/m3)
over a 1-year study period; TotalEDInpatient Vists = total number of emergency department or inpatient visits for respiratory issues
during a 1-year study period. The study period shown here is for calendar year 2010. AvgDailyPM2.5Exposure <3 range: 1.58, 9.63 μg/
m3; AvgDailyPM2.5Exposure ≥3 range: 9.63, 17.33 μg/m3. ID, identifier; PM2.5, airborne particulate matter ≤2.5 μm in diameter.

Clinical and Translational Science

Overview and Application of Clinical Data Types
Ahalt et al.
333

including genomic data and clinical records in semistructured JavaScript Object Notation or eXtensible Markup
Language formats. Genomic data typically consist of lists
of variants relative to a reference allele sorted by position.
Genome fingerprints capture the unique patterns generated by pairs of consecutive single-nucleotide variants
as patient-level matrices or fingerprints.10 The correlation
between two fingerprints reflects the degree of relatedness between two genomes. Clinical fingerprints similarly transform clinical records from the Fast Healthcare
Interoperability Resources format into numerical vectors
that greatly simplify their comparison. Translator team
members are working to adapt this methodology for application to the ICEES integration pipeline and incorporation into the ICEES integrated feature tables.
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CONCLUSION
1.

In this article, we described various types of clinical data
sets and associated inferential limitations and regulatory
constraints, focusing primarily on compliance requirements
mandated in the United States under HIPAA. We highlighted
several novel approaches that we have developed as part
of the Translator program to openly expose observational
patient data, while respecting and protecting patient privacy. We recognize that each of these approaches retains
a residual risk of patient reidentification; thus, we continue
to work with experts in regulatory protections and computer security to ensure that those risks remain minimal.
Although the Translator approaches are designed to be
disease-agnostic and generalizable, they were developed
to comply with HIPAA and institutional guidelines; as such,
our approaches may need to be modified prior to adoption
elsewhere. Nonetheless, through these open services, we
hope to accelerate clinical and translational science and
foster biomedical discovery.
Supporting Information. Supplementary information accompanies this paper on the Clinical and Translational Science website (www.
cts-journal.com). The Further Reading includes supplementary information on Clinical Profiles, Synthetic Clinical Datasets, COHD, and
ICEES, as well as relevant regulatory information and information on
related large-scale patient de-identification and data-sharing efforts.
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